Compositions and methods for inhibiting expression of Huntingtin gene
The invention relates to a double-stranded ribonucleic acid (dsRNA) for inhibiting the expression of the Huntingtin gene (HD gene), comprising an antisense strand having a nucleotide sequence which is less than 25 nucleotides in length and which is substantially complementary to at least a part of the HD gene. The invention also relates to a pharmaceutical composition comprising the dsRNA together with a pharmaceutically acceptable carrier; methods for treating diseases caused by the expression of the HD gene, or a mutant form thereof, using the pharmaceutical composition; and methods for inhibiting the expression of the huntingtin gene in a cell.
1. A double-stranded ribonucleic acid (dsRNA) for inhibiting the expression of a human Huntingtin gene in a cell, wherein said dsRNA comprises a sense strand consisting of SEQ ID NO:792 and an antisense strand consisting of SEQ ID NO:793.
2. The dsRNA of claim 1 , wherein said dsRNA comprises at least one modified nucleotide.
3. The dsRNA of claim 2 , wherein said modified nucleotide is chosen from the group of: a 2′-O-methyl modified nucleotide, a nucleotide comprising a 5′-phosphorothioate group, and a terminal nucleotide linked to a cholesteryl derivative or dodecanoic acid bisdecylamide group.
4. The dsRNA of claim 2 , wherein said modified nucleotide is chosen from the group of: a 2′-deoxy-2′-fluoro modified nucleotide, a 2′-deoxy-modified nucleotide, a locked nucleotide, an abasic nucleotide, 2′-amino-modified nucleotide, 2′-alkyl-modified nucleotide, morpholino nucleotide, a phosphoramidate, and a non-natural base comprising nucleotide.
5. A pharmaceutical composition for inhibiting the expression of the Huntingtin gene in an organism, comprising a dsRNA of claim 1 and a pharmaceutically acceptable carrier.
6. A method for inhibiting the expression of the Huntingtin gene in a cell, the method comprising:
(a) introducing into the cell a double-stranded ribonucleic acid (dsRNA) of claim 1 , and
(b) maintaining the cell produced in step (a) for a time sufficient to obtain degradation of the mRNA transcript of the Huntingtin gene, thereby inhibiting expression of the Huntingtin-gene in the cell.
7. The method of claim 6 , wherein said dsRNA is administered by in vivo to a mammal.
8. The method of claim 6 , wherein said dsRNA is administered by intrastriatal infusion.